OVID
Ovid Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.80
+0.72%Year over year
Reported trailing growth
- Revenue
- -76.2%
- EBITDA
- +7.4%
- EBIT
- -40.4%
- EPS
- +10.4%
- Free cash flow
- -36.6%
- Operating cash flow
- -36.7%
Forward estimates
Based on analyst estimates
- Revenue
- -63.9%
- EBITDA
- +23.1%
- EPS
- +22.3%
Three-year CAGR
- Revenue
- +69.0%
- EBITDA
- +70.4%
- EBIT
- +31.4%
- Net income
- +34.1%
- EPS
- +35.1%
- Free cash flow
- +31.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026